Literature DB >> 15823447

Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.

Mario Cazzola1, Paolo Noschese, Antonello Salzillo, Carlo De Giglio, Gennaro D'Amato, Maria Gabriella Matera.   

Abstract

We conducted a randomized, crossover trial with tiotropium 18 microg once daily (group A), and formoterol 12 microg twice daily (group B) over a 5-day period for each drug, with a 10-day washout, in 20 COPD patients. At the end of each period, patients inhaled both drugs separated by 180 min in alternate sequence (group A: tiotropium 18 microg+formoterol 12 microg; group B: formoterol 12 microg+tiotropium 18 microg). FEV1 and FVC were measured at baseline and after 30, 60, 120, 180, 210, 240, 300 and 360 min. FEV1 and FVC further improved after crossover with both sequences. The mean maximal change in FEV1 over baseline was 0.226 L (0.154-0.298) after tiotropium+formoterol and 0.228 L (0.165-0.291) after formoterol+tiotropium; the mean maximal change in FEV1 over pre-inhalation the second drug value was 0.081 L (0.029-0.133) after tiotropium+formoterol and 0.054 L (0.016-0.092) after formoterol+tiotropium. The mean maximal change in FVC over baseline was 0.519 L (0.361-0.676) after tiotropium+formoterol and 0.495 L (0.307-0.683) after formoterol+tiotropium; the mean maximal change in FVC over pre-inhalation of the second drug value was 0.159 L (0.048-0.270) after tiotropium+formoterol and 0.175 L (0.083-0.266) after formoterol+tiotropium. The FEV1 AUCs(0-360 min) were 62.70 (45.67-79.74) after tiotropium+formoterol and 69.20 (50.84-87.57) after formoterol+tiotropium, the FEV1 AUCs(0-180 min) were 24.70 (18.19-31.21) after tiotropium+formoterol and 29.74 (21.02-38.46) after formoterol+tiotropium, whereas the FEV1 AUCs(180-360 min) were 15.70 (10.88-20.52) after tiotropium+formoterol and 11.71 (7.21-16.21) after formoterol+tiotropium. Differences between the two treatments were not statistically significant (P>0.05). The addition of second different long-acting bronchodilator to a regularly administered long-acting bronchodilator seems to be to patient's advantage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15823447     DOI: 10.1016/j.rmed.2004.10.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

Review 1.  Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.

Authors:  R G Barr; J Bourbeau; C A Camargo; F S F Ram
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

Review 2.  Optimizing bronchodilator therapy in emphysema.

Authors:  Philip T Diaz; Aaron S Bruns; Michael E Ezzie; Nathaniel Marchetti; Byron M Thomashow
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

3.  Knowledge and attitudes of family physicians coming to COPD continuing medical education.

Authors:  Barbara P Yawn; Peter C Wollan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

4.  Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Authors:  Rashmi Mehta; Michelle Green; Bela Patel; Jonathan Wagg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-01-06       Impact factor: 2.745

5.  Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.

Authors:  Nicola A Hanania; Ahmad Boota; Edward Kerwin; LaTanya Tomlinson; Kimberly Denis-Mize
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 6.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease.

Authors:  Donald P Tashkin; Gary T Ferguson
Journal:  Respir Res       Date:  2013-05-08

Review 7.  Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.

Authors:  Eline L Huisman; Sarah M Cockle; Afisi S Ismaila; Andreas Karabis; Yogesh Suresh Punekar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-09

8.  Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK.

Authors:  Yogesh Suresh Punekar; Graeme Roberts; Afisi Ismaila; Martin O'Leary
Journal:  Cost Eff Resour Alloc       Date:  2015-12-12

9.  A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.

Authors:  Pascal L M L Wielders; Andrea Ludwig-Sengpiel; Nicholas Locantore; Suus Baggen; Robert Chan; John H Riley
Journal:  Eur Respir J       Date:  2013-02-21       Impact factor: 16.671

Review 10.  Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium.

Authors:  Cristoforo Incorvaia; Gian Galeazzo Riario-Sforza; Chiara Pravettoni; Mona-Rita Yacoub; Franco Frati
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.